Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SL

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Abbvie has completed a phase II upadacitinib vs combo elsubrutinib/upadacitinib ( ABBV-599) in active #SLE - M19-130 (SLEek) Phase 2 trial met the primary endpoint SRI-4 response and pred dose<=10 mg qd. No new safety signals - Phase III trial planned https://t.co/6CwS2AVamH https://t.co/b4wQ6IoiOz
Links
https://bit.ly/3nG1fJ5

Gender Gap in Editors. Cross-sect study of top 10 Intl medical journals in 41 categories shows women underrepresented as

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Gender Gap in Editors. Cross-sect study of top 10 Intl medical journals in 41 categories shows women underrepresented as editors in chief. Women editors=21%. No women editors in dentistry, oral surgery; allergy, psychiatry; anesthesiology; ophthalmology https://t.co/JWAwrO9F4w https://t.co/0viEMa6ImK
Links
https://bit.ly/3Uj8eEp

Variability in rheumatologist steroid prescribing - using data on ~500k RA pts and 6,875 rheumatologists. Those LESS lik

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Variability in rheumatologist steroid prescribing - using data on ~500k RA pts and 6,875 rheumatologists. Those LESS likely to prescribe alot of steroids were: women, solo practitioners, in practice ≥10 years, seeing greater#s of RA pts/year https://t.co/ELk0avorOe
Links
https://bit.ly/3U8T8B1

Open-label Trial of 14 pts with MAS due to steroid refractory systemic JIA or adult-onset Still’s demonstrated the eff

Social Author Image
https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3.jpg
Tweet Author
RheumNow
Social Author Name
Dr. John Cush
Tweet Content
Open-label Trial of 14 pts with MAS due to steroid refractory systemic JIA or adult-onset Still’s demonstrated the efficacy of IV emapalumab, an anti-IFNγ mAb. Demonstrated signif reductions in LDH, sIL-2R, Ferritin, CXCL9, & steroid dose https://t.co/vgxT5KzmQF https://t.co/gDLmfOlSHG
Links
https://bit.ly/3lV5RLb
3 April 2023
Women in Rheumatology: Gender Issues in Disease and Management
Nine videos discussing gender differences in axSpA, PsA, Vasculitis, Lung Disease, Osteoporosis, Disparities in Healthcare, and Rheumatologic Activity and Treatment, are now available.
3 April 2023
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks
The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.
3 April 2023
The Origin Story of RheumNow’s Campaign: Women in Rheumatology--The XX Factor

Origin stories have captivated me ever since my childhood spent reading Greek Mythology and Marvel comic books. Superheroes have different powers and personalities. Some could fly, others were strong and seemed invincible, most were intelligent, but all fought for the good of humanity.  

Gender Risk in Rheumatic Disease

ADD THE FIRST COMMENT

Career & Family Issues

Do you frequently miss significant life events due to work obligations?

Do personal/family/life events affect your work?

How often do you take time for self-care (exercise, hobbies, travel, etc.)?

Do you feel you have a good work-life balance currently?

Have you experienced work/career burn out?

Would you recommend rheumatology to women entering medicine?

I am:

It looks like you can vote in this survey!

Click on the button to cast your vote.

Vote!
Subscribe to
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×